Clearmind's CMND-100 Drug for Alcohol Use Disorder Achieves Primary Endpoint in Phase I/IIa Trial
CMND has more than doubled off its 52-week low of $0.595.
Summary
Clearmind Medicine announced that its CMND-100 drug candidate for Alcohol Use Disorder (AUD) successfully met the primary endpoint in its FDA-approved Phase I/IIa clinical trial. The trial results, including data from the third cohort, indicated a high safety profile and favorable tolerability for CMND-100, with no serious adverse events reported even at higher dosages. This positive outcome follows earlier reports of completing treatment and follow-up for various cohorts in the same trial. For a clinical-stage biotech company with a small market capitalization, meeting the primary safety and tolerability endpoint is a critical de-risking event, validating the drug's foundational safety profile. This significant milestone supports the continued advancement of CMND-100 as a potential novel, non-hallucinogenic treatment option for AUD. Investors will now anticipate further updates on the drug's development pathway, including plans for subsequent clinical trials and any preliminary efficacy data.
At the time of this announcement, CMND was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.59 to $52.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.